Effect of minocycline on changes in affective behaviors, cognitive function, and inflammation in breast cancer survivors undergoing chemotherapy: a pilot randomized controlled trial
Effect of minocycline on changes in affective behaviors, cognitive function, and inflammation in breast cancer survivors undergoing chemotherapy: eine pilotierte randomisierte kontrollierte Studie
Breast Cancer Research and Treatment · 2024-12 · 208 (3) · 605-617
DOI: 10.1007/s10549-024-07457-w ↗Auf einen Blick
In einer pilotierten RCT bei Frauen mit Brustkrebs unter Chemotherapie veränderte Minocyclin Affekt, Kognition und Entzündungsmarker insgesamt nicht. Nur IL-8 und depressive Symptome in einer Subgruppe verbesserten sich.
Fragestellung
Wirkt orales Minocyclin im Vergleich zu Placebo auf affektive Symptome, Kognition und Entzündung bei Frauen mit Brustkrebs unter Chemotherapie?
Methode
Pilotierte, doppelblinde, randomisierte kontrollierte Studie mit oralem Minocyclin 100 mg BID versus Placebo bei Frauen mit Stadium I–III Brustkrebs; Messungen bis 6 Monate nach Chemotherapie.
Ergebnisse
57 Frauen wurden eingeschlossen, 55 beendeten die Studie. Für CES-D, STAI, Kognition und die meisten Entzündungsmarker zeigten sich keine Gruppenunterschiede (alle p > 0,05). IL-8 unterschied sich (p ≤ 0,03); in der depressiven Subgruppe sank CES-D stärker (p = 0,01).
Schlussfolgerung der Autor:innen
Trotz Abschwächung von IL-8 veränderte Minocyclin bei dieser Kohorte keine selbstberichteten affektiven Symptome oder die Kognition. Der Effekt bei Frauen mit depressiven Symptomen vor der Chemotherapie sollte weiter untersucht werden.
Kernaussagen
- Keine Gruppenunterschiede bei CES-D, STAI oder Kognition
- IL-8 nahm unter Minocyclin weniger zu
- Subgruppe mit Depression: stärkere CES-D-Abnahme
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 14.08.2024. Verfasst von Zihan Melink und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Sciences, The Ohio State University, Columbus, OH, 43210, USA. Hauptthemen laut MEDLINE: Minocycline, Breast Neoplasms, Cancer Survivors, Cognition. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
Minocycline suppresses chemotherapy-induced neuroinflammation in preclinical models, but its effects in cancer survivors are unknown. This study evaluated the longitudinal effects of minocycline on affective behaviors, cognitive functions, and inflammation in women with breast cancer (BC) undergoing chemotherapy.
Methods
This is a pilot, double-blind, randomized controlled trial of oral minocycline (100 mg BID) versus placebo for chemotherapy-induced affective disorders in women initiating chemotherapy for stage I–III BC. Participants received minocycline or placebo up to one week before chemotherapy, continuing through cycle 4 (C4). Epidemiologic Studies Depression Scale (CES-D) and State-Trait Anxiety Inventory (STAI) were assessed at baseline, each cycle of chemotherapy (C1–C4), 2–3-week post-chemotherapy (end of chemotherapy), and 6-month post-chemotherapy (6 M) as the primary outcomes. Sub-group analysis of CES-D and STAI based on the severity of symptoms was also performed. Changes in self-reported cognition and serum inflammatory markers were also evaluated.
Results
Fifty-seven women enrolled and 55 completed the study. Except for Interleukin-8 ( p ≤ 0.03), changes in inflammatory markers, cognitive function, CES-D, and STAI were not significantly different between groups from baseline to any cycle or post-chemotherapy time point (all p > 0.05), adjusting for baseline scores. Increases in serum Interleukin-8 from baseline to C4 and 6 M were ameliorated by minocycline ( p < 0.05). The sub-group symptomatic for depression (CES-D > = 16 at baseline) treated with minocycline had a greater reduction in CES-D score compared to placebo from baseline to 6 M ( p = 0.01).
Conclusion
Despite attenuation of IL-8, minocycline did not alter self-reported affective symptoms or cognition in this cohort of BC survivors undergoing chemotherapy. The effect of minocycline on BC survivors symptomatic for depression before chemotherapy warrants further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Sciences, The Ohio State University, Columbus, OH, 43210, USA.
- Yale School of Medicine, Center for Breast Cancer, New Haven, CT, 06511, USA.
- Division of Biostatistics, College of Public Health, The Ohio State University, Columbus, OH, 43210, USA.
- Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
- Department of Human Sciences, The Ohio State University, Columbus, OH, 43210, USA. orchard.6@osu.edu.
Förderung
- NCATS NIH HHS
Zitieren
APA
Melink, Z., Lustberg, M. B., Schnell, P. M., Mezzanotte-Sharpe, J., & Orchard, T. S. (2024). Effect of minocycline on changes in affective behaviors, cognitive function, and inflammation in breast cancer survivors undergoing chemotherapy: a pilot randomized controlled trial. Breast Cancer Research and Treatment, 208(3), 605-617. https://doi.org/10.1007/s10549-024-07457-w
Vancouver
Melink Z, Lustberg MB, Schnell PM, Mezzanotte-Sharpe J, Orchard TS. Effect of minocycline on changes in affective behaviors, cognitive function, and inflammation in breast cancer survivors undergoing chemotherapy: a pilot randomized controlled trial. Breast Cancer Research and Treatment. 2024;208(3):605-617. doi:10.1007/s10549-024-07457-w
BibTeX
@article{Melink2024,
author = {Melink, Zihan and Lustberg, Maryam B and Schnell, Patrick M and Mezzanotte-Sharpe, Jessica and Orchard, Tonya S},
title = {Effect of minocycline on changes in affective behaviors, cognitive function, and inflammation in breast cancer survivors undergoing chemotherapy: a pilot randomized controlled trial},
journal = {Breast Cancer Research and Treatment},
year = {2024},
volume = {208},
number = {3},
pages = {605--617},
doi = {10.1007/s10549-024-07457-w}
}
EUVIMED